Protalix BioTherapeutics, Inc.
PLX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $20 | $24 | $17 | $39 |
| Short-Term Investments | $15 | $21 | $5 | $0 |
| Receivables | $3 | $5 | $5 | $3 |
| Inventory | $21 | $19 | $17 | $18 |
| Other Curr. Assets | $1 | $1 | $1 | $1 |
| Total Curr. Assets | $60 | $70 | $45 | $62 |
| Property Plant & Equip (Net) | $10 | $11 | $10 | $10 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $3 | $3 | $0 | $0 |
| Other NC Assets | $0 | $1 | $1 | $2 |
| Total NC Assets | $13 | $15 | $11 | $12 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $73 | $84 | $56 | $74 |
| Liabilities | – | – | – | – |
| Payables | $5 | $4 | $6 | $7 |
| Short-Term Debt | $2 | $23 | $1 | $1 |
| Tax Payable | $3 | $3 | $1 | $0 |
| Deferred Revenue | $0 | $0 | $13 | $9 |
| Other Curr. Liab. | $16 | $15 | $12 | $16 |
| Total Curr. Liab. | $26 | $46 | $32 | $33 |
| LT Debt | $4 | $5 | $32 | $32 |
| Deferred Rev, NC | $0 | $0 | $0 | $12 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $1 | $1 | $2 | $2 |
| Total NC Liab. | $5 | $5 | $34 | $47 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $6 | $6 | $5 | $6 |
| Total Liabilities | $30 | $51 | $66 | $80 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$378 | -$382 | -$390 | -$375 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $422 | $415 | $379 | $369 |
| Total Equity | $43 | $34 | -$11 | -$6 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $73 | $84 | $56 | $74 |
| Net Debt | -$14 | $4 | $16 | -$6 |